MedTrace Logo

The Opal - COVID-19 Study

NCT04978233 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-07-27

No results posted yet for this study

Summary

In collaboration with involved healthcare professionals and a patient advisory committee, this study tests the feasibility of using the Opal smartphone app to daily capture self-reported physical and psychological symptoms and vital signs among 50 people who are self-isolating at home with COVID-19. A healthcare team at Montreal's MUHC will remotely monitor their condition and offer advice and teleconsultations, as needed.

Conditions

Interventions

OTHER

sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID

The intervention consists of having confirmed COVID-19 infected participants register for the Opal app and complete a daily questionnaire on symptoms related to their physical and mental health as well as on certain key vital signs (e.g., oxygen saturation, heart rate, temperature). A nurse will check the questionnaire results each day and determine the need for a teleconsultation with an infectious disease physician. Participants will be followed up for a minimum of 14 days, depending on their symptoms.

Sponsors & Collaborators

  • Dr. Bertrand Lebouche

    lead OTHER

Principal Investigators

  • Bertrand Lebouché, MD · McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-08
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04978233 on ClinicalTrials.gov